Search
for
Sort by
Research 31–60 of 1000+
- Modern Management Approaches for Alopecia Areata
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
- Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention
- Treating Alopecia Areata: Current Practices Versus New Directions
- Mechanisms of autophagy and their implications in dermatological disorders
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
- DataSheet1_Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention.PDF
- Updates From 2021 Virtual Dermatology Nurses' Association Convention
- Diagnostic Challenges and Treatment Strategies in Neutrophilic Cicatricial Alopecias: A Narrative Review from Conventional Therapies to New Therapeutic Targets
- CURRENT UNDERSTANDING OF VITILIGO: A COMPREHENSIVE LITERATURE REVIEW
- The JAK/STAT signaling pathway: from bench to clinic
- SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report
- Ritlecitinib: First Approval
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Baricitinib for the Treatment of Alopecia Areata
- Hair growth–promoting effects of Enz_MoriL on human dermal papilla cells through modulation of the Wnt/β-Catenin and JAK-STAT signaling pathways
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
- Chemistry42: An AI-Driven Platform for Molecular Design and Optimization